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Abstract
Background: Adherence to prevention, care, and treatment recommendations among people living with HIV (PLHIV) is a
critical challenge. Yet good clinical outcomes depend on consistent, high adherence to antiretroviral therapy (ART) regimens.
Mobile phones offer a promising means to improve patient adherence and health outcomes. However, limited information exists
on the impact that mobile phones for health (mHealth) programs have on ART adherence or the behavior change processes through
which such interventions may improve patient health, particularly among ongoing clients enrolled in large public sector HIV
service delivery programs and key populations such as men who have sex with men (MSM) and female sex workers (FSW).
Objective: Our aim is to evaluate an mHealth intervention where text message reminders are used as supportive tools for health
providers and as motivators and reminders for ART clients to adhere to treatment and remain linked to care in Ghana. Using an
implementation science framework, we seek to: (1) evaluate mHealth intervention effects on patient adherence and health outcomes,
(2) examine the delivery of the mHealth intervention for improving HIV care and treatment, and (3) assess the cost-effectiveness
of the mHealth intervention.
Methods: The 36-month study will use a facility cluster randomized controlled design (intervention vs standard of care) for
evaluating the impact of mHealth on HIV care and treatment. Specifically, we will look at ART adherence, HIV viral load,
retention in care, and condom use at 6 and 12-month follow-up. In addition, participant adoption and satisfaction with the program
will be measured. This robust methodology will be complemented by qualitative interviews to obtain feedback on the motivational
qualities of the program and benefits and challenges of delivery, especially for key populations. Cost-effectiveness will be assessed
using incremental cost-effectiveness ratios, with health effects expressed in terms of viral load suppression and costs of resources
used for the intervention.
Results: This study and protocol was fully funded, but it was terminated prior to review from ethics boards and study
implementation.
Conclusions: This cluster-RCT would have provided insights into the health effects, motivational qualities, and cost-effectiveness
of mHealth interventions for PLHIV in public sector settings. We are seeking funding from alternate sources to implement the
trial.
(JMIR Res Protoc 2015;4(1):e11)   doi:10.2196/resprot.3659
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Introduction
Background
Adherence to prevention, care, and treatment recommendations
among people living with HIV (PLHIV) is a critical challenge
facing HIV service delivery programs. Myriad personal, social,
and systems level barriers influence adherence among PLHIV
on antiretroviral therapy (ART). Difficulty managing treatment
and forgetting to take medications or attend clinic appointments
are common reasons for poor adherence [1-4]. Lack of social
support, negative perceptions, poor communication with
providers, and stigma and discrimination also may limit
adherence [2,3]. In resource-poor settings, adherence challenges
are amplified by structural and economic constraints such as
residential dispersion that requires long travel times and has
costs associated with travel and wage loss [3,4]. Key populations
are disproportionately less likely to access and remain in care
and treatment compared to the general population of PLHIV
[5]. Good clinical outcomes depend on high adherence;
consistent adherence to ART regimens is associated with
reduced HIV RNA (viral load) levels, decreased transmission,
higher CD4 cell counts, lower health care costs, and overall
improved quality of life [6-9].
Mobile phones offer a promising means to improve patient
adherence and health outcomes because they are private,
portable, increasingly affordable, and nearly ubiquitous (88%
use in Ghana [10]). Mobile phone interventions provide a means
to address several of the key barriers to good adherence by
providing reminders for care and a direct connection to health
providers and facilities [11,12]. Research conducted in East
Africa has shown that texting (short message service, SMS)
reminders to ART clients’ mobile phones improved adherence
and health [13-15]. Due to favorable findings from mobile
phones for health (mHealth) interventions, limited proven
adherence and treatment support interventions [3,16,17], and
the need for a combination of interventions to address the
complexities of adherence, mHealth programs are rapidly being
scaled up globally [18,19].
Justification for Study
Implementation research is needed to keep pace with mHealth
program scale-up to provide guidance for optimal delivery and
effectiveness of mHealth programs [3,18,20-22]. Although
mobile phone reminders have been shown to improve
medication adherence among new ART clients in a few health
facilities, a trial conducted in one health facility in Cameroon
with continuing ART clients did not improve adherence [21].
We have limited information about mHealth program effects
on continuing ART clients and subpopulations in large-scale,
public-sector HIV care and treatment programs where the
majority of PLHIV in Ghana seek HIV care. Since women and
key populations eg, female sex workers (FSW), and men who
have sex with men (MSM), continue to be disproportionally
affected by HIV, it is critical to assess effectiveness among
these groups [3,5]. Moreover, the need for adherence support
may be greater among continuing ART clients as opposed to
new ART clients, as adherence challenges grow over time
[23,24]. The support provided by mHealth interventions may
influence ART clients’ adherence as well as retention in HIV
care and treatment and adherence to other prevention and care
directives such as use of condoms. Furthermore, there is little
evidence about the motivational behavior change processes
through which mHealth interventions improve patient health
[25]. It is imperative to understand when, why, and how
interventions work to develop a sound understanding of
effectiveness to inform program scale-up [25,26]. Lastly,
decision-makers and program implementers need mHealth
cost-effectiveness data to guide resource allocation [14,27,28].
Study Objectives
The main study goal is to evaluate the impact, implementation,
and cost-effectiveness of a mobile phone adherence support
intervention delivered to patients on ART in large-scale public
sector health services in Ghana, especially for women and key
populations. The study has three objectives: (1) to evaluate
mHealth intervention effects on patient adherence and health
outcomes; (2) to examine the delivery of the mHealth
intervention for improving HIV care and treatment; and (3) to
assess the cost-effectiveness of the mHealth intervention.
Methods
Study Design
This study is a two-arm, facility randomized, open, controlled
trial. Of the public-sector health facilities in Ghana that provide
ART to PLHIV in conjunction with the National AIDS Control
Program (NACP)/Ghana Health Services (GHS), 40 will be
randomly and equally allocated to receive either the mHealth
intervention or standard of care. Approximately 1600 PLHIV
who have been on ART for at least 6 months and who own a
mobile phone will be enrolled. Data collection will occur at
baseline and 6 and 12 months post-enrollment. A subsample of
women and intervention participants from key populations
including MSM and FSW, and health care providers and
managers at intervention facilities, will be randomly selected
to complete qualitative interviews at follow-up.
Facility Eligibility and Recruitment
The study will be implemented in health facilities in five regions
of Ghana that have sufficient numbers of people on ART in
public sector facilities and are accessible to study staff for data
collection and monitoring. Specifically, eligible facilities must
have at least 150 patients enrolled on ART, follow the national
Ministry of Health guidelines for ART care and treatment [29],
be a NACP/GHS facility, and they must not be extremely
difficult to access due to very remote location or poor
infrastructure for reaching the facility. To maximize facility
homogeneity while balancing representativeness of clinics and
participants, facilities meeting eligibility criteria will be stratified
by geography (urban and rural) and number of ART patients
receiving services. Facilities then will be recruited for study
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participation in proportion to their representation in the eligible
facility population across strata until the target number of
facilities is attained.
Participants
Eligibility
To be in the study, participants must be between 18-49 years
old, currently receiving ART at public sector facilities, enrolled
in ART for a minimum of 6 months, and own a mobile phone.
They also must live near the study facility and plan on residing
near it for 12 months following study enrollment. Study
volunteers who are currently participating in another HIV
adherence study or who were involved in the mHealth pilot
intervention will be excluded.
Recruitment
Potential participants initially will be informed about the study
by implementing partners at support groups and at the study
clinics. In addition, peer educators who work with PLHIV will
tell MSM and FSW about the study. Facility staff and clinicians
also may apprise patients about the study. Interested PLHIV
will be encouraged to speak with study staff at the facilities
during predetermined study recruitment times; these times will
be arranged during medication refill days or other times when
substantive numbers of potential participants are likely to be in
study facilities. Screening and enrollment will take place for
interested volunteers in a private location in each health facility,
where eligible participants will be enrolled until the target
sample size is attained. Participants from intervention facilities
will be enrolled into the mHealth intervention at enrollment. It
is estimated that recruitment will take approximately 6 months
to complete.
Informed Consent
Participation will require written informed consent. Informed
consent will be administered in English or Twi, the local
language.
Randomization
Once facilities are identified and agree to participate, they will
be randomized within strata (urban/rural and number of ART
patients) to the intervention or control group. Facility assignment
will be revealed to field staff just prior to study initiation. Group
assignment is needed before enrolling individuals and no
blinding is possible. Eligible individual participants will receive
the intervention or standard of care according to the assignment
of the facility where they receive their HIV care and ART
medication.
Intervention: LifeLine
The mobile phone intervention, termed LifeLine, was developed
and piloted as one component of the Unites States Agency for
International Develop (USAID) Ghana project, Strengthening
HIV/AIDS Partnerships with Evidence-based Results
(SHARPER). SHARPER partners with 25 local
non-governmental organizations (NGOs), the Ghana AIDS
Commission, and the Ghana Health Service to increase healthy
behaviors and access to HIV prevention and care services among
MSM and FSW and their intimate partners, and PLHIV and
their partners. LifeLine is a one-way text messaging service;
participants receive but do not respond to the messages via
mobile phone. A local technological partner will provide support
for the fully automated LifeLine program, including enrollment
of LifeLine participants from mobile phone numbers provided
by study staff.
The LifeLine intervention sends daily text message ART
reminders at no cost to PLHIV upon enrollment into the
program. The messages were developed with input from both
PLHIV and members of key populations. Many different
messages have been developed and will be rotated
approximately every 3 months. Daily messages refer to
“medication” rather than drugs or ART, and data from pilot
testing showed high acceptability, recall, and sharing of
messages. Sample LifeLine messages include:
Taking my medicine every day makes me stay healthy
to work and take care of myself and family.”
It is my life and I will make sure that nothing stops
me from taking my medicine.”
Good morning! How are you today? Please remember
your medication. Stay blessed!”
Control
In the control condition, participants will receive usual care.
This consists of the essential package of services specified by
the Ministry of Health Guidelines for Antiretroviral Therapy in
Ghana [29]. Services include ART adherence monitoring
through self-report and pill counts, in-depth discussion of ART
adherence at each treatment visit, regular CD4 testing,
management of sexually transmitted infections (STIs),
management of opportunistic infections, referrals and linkages
within and outside the health system, and regular patient reports
through the health information system. For patients who have
been on ART for 6 months or more, regular visits are scheduled
every 3 to 6 months unless there is an urgent health need, and
CD4 testing is conducted twice per year.
Sample Size
We calculated that a sample size of 40 clinics with 40 completed
participants per clinic on average for a total of 1600 PLHIV is
needed to detect a 15% improvement in adherence at 12 months,
with 84% power and a (two-tailed) significance level of 0.05.
These calculations assume that, at baseline, 65% of enrolled
participants will be defined as having good ART adherence
according to national guidelines (>90% adherent in Ghana). We
have assumed approximately 20% participant attrition over the
life of the study and have increased participant recruitment
targets accordingly (N=2000). These calculations assume an
intra-class correlation coefficient (ICC) of 0.05 due to the
enrollment of participants and randomization by facility. The
correlation (stability) in self-reported adherence over time that
occurs within both clinics and subjects is assumed to be .50.
Study Measures
Health Outcomes
Study health outcomes are ART adherence [23,30,31], viral
load, retention in care [32,33], and condom use (Table 1).
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Routine data collection for clinical care related to ART
adherence and health outcomes and tracking already occurs in
the public sector NACP/GHS health facilities. These data are
collected electronically by trained Strategic Information/
Monitoring & Evaluation staff employed by each facility and
supervised by the NACP/GHS. This will be augmented with a
supplemental data collection form administered to all
participants at enrollment and 6 and 12-month follow-ups.
Table 1. Overview of measures.
M12M6M0Data sourceIndicatorsMeasures
Health Outcomes
XXXClinical care data; pharmacy
records
Self-report in given time period; self-report via visual
analog scale; pharmacy refills
ART adherence
XXLaboratory testingUndetectable plasma HIV viral load (<400 copies/ml)Viral suppression
XXClinical care dataClient tracking outcomes: stopped treatment, known
to be dead, or lost to follow-up
Retention in care
XXXClinical care dataConsistency of use and use at last sex with different
partners (main, casual)
Condom use
Implementation Measures
XXXSupplemental data collectionSelf-efficacy for taking ART; perceived social support
for adherence; motivation for adherence; perceived
quality and access to providers/facilities
Health behaviors
XaXaSupplemental data collec-
tion; qualitative interviews
Satisfaction with intervention; message receipt and
recall; privacy and confidentiality concerns; message
relevance and trust; message sharing; actions taken on
receiving messages; use of additional mobile phone
services
mHealth intervention adop-
tion
XaXaTechnology system logs;
supplemental data collection
Messages sent on-time; messages receivedFidelity of intervention deliv-
ery
XbQualitative interviewsBenefits and challenges to intervention implementa-
tion; intervention impact on PLHIV quality of care;
integration with health system
Provider perspectives
Costing Measures
XXXIntervention tracking tool;
costing forms
Training; additional staff time; travel for counselors;
other
Costs of routine care
XXXIntervention tracking tool;
costing forms
Initial software and hardware/server costs; maintenance
for software and server; maintenance for tech support;
monthly reporting; SMS costs; message development
Costs of intervention
aMeasures administered in intervention facilities only.
bProvider interviews will take place approximately nine months after intervention initiation in intervention facilities only.
Implementation Measures
This aspect of the study will use a theory-based evaluation
approach to assess how and why the mHealth intervention works
for PLHIV and key populations on ART [26]. The research will
focus on how the mHealth intervention addresses behavioral,
social, and cognitive change strategies. Study participants in
both intervention and control groups will be asked about their
motivation for good health and management of HIV disease in
the supplemental data collection form. These health behavior
constructs may influence the primary study outcomes, and they
may mediate the impact of the mHealth intervention on these
outcomes. In addition, to assess reasons for and barriers to
mHealth intervention adoption, as well as consistency and
timeliness of receipt of text messages, a few questions will be
added to the supplemental data collection form for intervention
facilities only. Intervention fidelity also will be assessed through
review of system logs from the technology provider to check
for on-time and same-time of day delivery of text messages to
intervention participants.
To explore implementation issues that may be unique for women
and/or key populations living with HIV, qualitative in-depth
interviews will further assess confidentiality and privacy
concerns, message relevance and trust, and other program
delivery and adoption issues, in addition to assessing opinions
about the motivational aspects of the intervention. Interviews
also will include questions about the social support function of
mobile phones, probing on how the intervention may increase
perceptions of social support from health care providers and
PLHIV, as well as how social support may be increased by
sharing of messages with family and friends. Finally, interviews
will include questions about how participants’ use of the
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mHealth intervention may have affected their use of mobile
phones for other information and services, particularly for
women and key populations. A minimum of three interviews
per intervention facility will be conducted.
The health care provider qualitative interviews will focus on
benefits and challenges to implementing mHealth interventions
in health facilities and with clients, as well as to integrating
mHealth components into larger health systems in general. One
health care provider and one manager will be interviewed in
each facility.
Costing Measures
Costs will be assessed for implementing the standard of care in
NACP/GHS facilities, as well as costs for implementing the
LifeLine mHealth intervention. Information from NACP/GHS
facility and SHARPER program records will be extracted to
account for retrospective and prospective costs, detailed using
an Intervention Tracking Tool (ITT) and accompanying
prospective costing forms.
Analysis
Primary Analyses
Generalized estimating equations (GEE) will be applied to
compare intervention and control arms on the key 6 and
12-month health outcomes. In order to adjust for variance in
the outcomes at the facility-level, compound symmetric working
correlation matrices will be used in all models. In order to
maximize statistical power, all models will control for baseline
measures of the outcomes. In addition, all models will include
sex, stratification variables, and time on ART, as well as other
covariates identified from the literature and to be specified in
the final statistical analysis plan. Hypotheses will be tested at
the 5% significance level for two-sided comparisons.
Mediation Analyses
In addition, we plan to explore the mediating effects of health
behavior constructs such as self-efficacy for taking ART and
using health services and perceived social support from health
providers, PLHIV, and partners. In mediation analyses, we will
estimate both the impact of the intervention on these factors as
well as associations between these factors and the post
intervention outcomes to partition any observed impacts of
treatment into direct and indirect effects. The analytic approach
will be based on path analyses using regression analyses or
structural equation modeling.
Qualitative Analyses
A qualitative data software program, such as QSR Nvivo or
QDA Miner, will be used to organize, code, and analyze all
qualitative data. Inter-rater reliability checks will be conducted
periodically during data coding and analysis, and quantitative
coefficients such as Scott’s Pi or Cohen’s Kappa may be used
to assess the extent of agreement between coders. Coded data
will be analyzed for themes according to the study objectives
and research questions. Data will be compared across women,
men, and key populations (MSM and FSW) to identify
similarities and differences in their reactions to and opinions
about the mHealth intervention. Data from facility staff will be
analyzed separately from intervention participant data.
Cost Effectiveness Analysis
To determine the incremental cost-effectiveness ratio (ICER)
of LifeLine, we will relate incremental costs (the numerator) to
health effects (the denominator). Specifically, the numerator
for the ICER will be calculated as the additional costs associated
with implementing the LifeLine program beyond the standard
of care. The denominator for the ICER will be calculated from
the change in proportion virally suppressed at 12-month
follow-up in the LifeLine intervention group compared to the
change in proportion virally suppressed in the standard of care
group.
Sensitivity analyses will be conducted to model
cost-effectiveness under different parameters, such as lower
text message costs that may be negotiated with mobile network
operators. A tornado diagram will be generated to visually
represent the resulting sensitivity analyses to show the costs
and savings associated with different scenarios. In addition, the
World Health Organization (WHO) threshold for
cost-effectiveness [34] of an ICER lower than three times gross
domestic product per person will be considered in presenting
results from cost-effectiveness analyses. Affordability also will
be considered in evaluating cost effectiveness of the
intervention; for example, intervention costs and the ICER will
be compared to country expenditures on health.
Results
This study was funded through a competitive call for
Implementation Science Research to Support Programs under
the President’s Emergency Plan for AIDS Relief (PEPFAR)
Round 2. However, leading up to protocol review and approval,
continued funding for the mHealth intervention under study
became uncertain; as a result, there was not a guarantee that the
intervention would remain active for the entire study period.
Therefore, the funder and the study implementer made a mutual
decision to terminate the study, and the study was terminated
prior to ethics approval of the protocol. We are currently seeking
funding from alternate sources to implement this study.
Discussion
Summary
To our knowledge, the current study would be the first clinical
trial to examine the effects of mHealth for HIV prevention and
care among PLHIV in a scaled-up public sector setting. Results
from this study would inform development of guidelines for
achieving improved clinical benefits and recommendations for
mHealth service delivery, from the clinic to national and
international policy levels. Findings also would contribute to
understanding how mobile technology interventions motivate
better health, as well as how they function when integrated into
larger health systems. Furthermore, this study protocol may
provide guidance to HIV and mHealth experts who are seeking
to evaluate mobile phone programs for HIV prevention, care,
and treatment. The protocol focuses on mHealth impact at the
clinical, care, and behavioral levels; investigation of
implementation issues unique to mHealth interventions; and
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the costing component all are priorities for evidence generation
in the area of mobile phones for health.
Limitations
There are a few study limitations worth noting. Supplementing
routine data collection for ART clients with study-specific data
collection reduces costs and participant burden; however, in
collaboration with partners and facilities, great care will need
to be taken to ensure high quality data, whether routine or
study-specific, and across all time points. Self-reported
adherence to ART has notable limitations, and we will
complement self-reported data with objective measures from
pharmacy, clinician, and laboratory data to provide a
triangulated perspective on ART adherence. The health behavior
constructs we will assess have rarely been evaluated in mobile
phone interventions, but focus group data from LifeLine pilot
participants suggests that the proposed constructs are impacted
by mHealth programs. Finally, we will not be able to control
external factors that may confound study results, such as
medication supplies or health system challenges, civil or political
influences, or other health or technology programs occurring
in study communities during the intervention period, although
we will document these contextual factors to help with
interpretation of findings.
Conclusions
This study is poised to make a substantive contribution to the
evidence base for using mHealth strategies to improve HIV
service delivery. Study results may advance the field of HIV
service delivery by providing: appropriate and robust scientific
methodologies for evaluating mHealth interventions for care
and treatment; guidelines for achieving improved clinical
benefits for specific populations (eg, women, key populations,
time on ART) from mHealth reminders for care and treatment;
recommendations (including cost-effectiveness) for service
delivery programs and health systems that are planning or
implementing mHealth interventions for care and treatment;
and improved understanding of how mobile technology
interventions motivate better health through use of behavioral,
social, and cognitive strategies.
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